Effect of HSV-2 Suppressive Therapy on Sexual Behavior

Status Terminated

Clinical Trial Summary

The purpose of this study is to determine what effect suppressive therapy has on sexual behavior and quality of life among persons with genital herpes (HSV) who have multiple sex partners. Study terminated; investigator relocated and study funding ended. Results were never analyzed because data were not collected.

Clinical Trial Description

We plan to conduct a randomized controlled trial of chronic suppressive acyclovir, 400 mg orally twice daily (standard dose) versus episodic acyclovir for treatment of genital herpes recurrences. We will enroll 500 HSV-2 seropositive single persons (250 per arm), stratified by gender and history of symptomatic genital herpes, and prospectively follow them for 1 year to assess sexual behavior, adherence to therapy, and herpes-related quality of life. These outcomes will be measured by self-report in a confidential, computer-based assessment. We plan to use data from this trial to model the effect that increasing the proportion of sexually-active HSV-2 infected persons taking suppressive therapy will have on population-level incidence and prevalence of HSV-2. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00495716
Study type	Interventional
Source	University of Washington
Contact
Status	Terminated
Phase	Phase 4
Start date	January 2008
Completion date	June 2010

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT06033261` - A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes	Phase 1/Phase 2
Completed	`NCT01132716` - Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions	N/A
Completed	`NCT01132729` - Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions	N/A
Completed	`NCT00362297` - Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2	Phase 4
Completed	`NCT03831165` - Melatonin Effects on Genital Herpes in Brazilian Women	Phase 4
Terminated	`NCT01658826` - Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes	Phase 2
Completed	`NCT00262106` - Trial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection	Phase 3
Completed	`NCT01346475` - Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2	Phase 4
Completed	`NCT01390805` - Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis)	N/A
Terminated	`NCT03146403` - Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection	Phase 2
Completed	`NCT03080961` - The VIBLOK SAfety and perFormancE Trial	N/A
Completed	`NCT00231049` - Trial Evaluating Safety, Tolerability and Immune Response of AG-707	Phase 1
Completed	`NCT00306787` - Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes	Phase 3
Completed	`NCT00495573` - HSV-2 Shedding Resolution After Acyclovir Treatment	N/A
Completed	`NCT00477334` - Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients	Phase 4
Not yet recruiting	`NCT03595995` - A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621	Phase 2
Completed	`NCT01281007` - Efficacy of Oral Famciclovir 125mg Comparing to Aciclovir 200 mg Treatment in Patients With Active Recurrent Genital Herpes	Phase 3
Completed	`NCT01112956` - Serologic Assays for the Diagnosis of Herpes Simplex Virus Type 2	N/A
Completed	`NCT00129818` - A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding	Phase 4
Completed	`NCT00808405` - GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women	N/A